Two pharmaceutical companies have partnered  and submitted a new drug application to the Japanese Ministry of Health, Labour, and Welfare to manufacture and market the drug therapy, LUPKYNIS® (voclosporin), for the treatment of lupus nephritis, (LN, lupus-related kidney disease). 

LUPKYNIS is a novel, structurally modified calcineurin inhibitor (CNI) that works in two ways – acting as an immunosuppressant through inhibition of T-cell activation and cytokine production, and by promoting podocyte stability in the kidney. 

Continue to follow the Lupus Foundation of America for updates on lupus drug developments and clinical trials. Learn more about LUPKYNIS.

Read the announcement